ArticleInternational journal of clinical oncology2026
The changes of CD47 and PD-L1 (SP142) before and after neoadjuvant therapy help predict prognosis of patients with stage IIIA-N2 non-small cell lung cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNon-small cell lung cancer (NSCLC) represents over 80% of lung cancer cases. Neoadjuvant therapy (NAT) improves overall survival (OS) of NSCLC patients. We explored clinicopathological significance of pre- and post-NAT CD47 and PD-L1 (SP142) changes [ΔCD47, ΔPD-L1 (SP142)] in stage IIIA-N2 NSCLC patients.
methodsTotally 137 stage IIIA-N2 NSCLC patients underwent post-NAT surgery were selected, with tissues and clinical data collected. CD47 and PD-L1 (SP142) were determined by RT-qPCR and immunohistochemistry, with their relationships with chemotherapy efficacy and the tumor regression grade (TRG) score analyzed. The predictive value of CD47 and PD-L1 (SP142) for poor prognosis and their effects on OS and progression-free survival (PFS), and independent risk factors (IRFs) for poor 5-year prognosis were analyzed by receiver operating characteristic, Kaplan-Meier curves, and COX univariate/multivariate regression models.
resultsPost-NAT CD47 and PD-L1 (SP142) were reduced in stage IIIA-N2 NSCLC patients. Higher ΔCD47 and ΔPD-L1 correlated with worse chemotherapy efficacy. Post-NAT ΔCD47 and ΔPD-L1 (SP142) were reduced in patients with major pathological response. ΔCD47 and ΔPD-L1 positively correlated with TRG scores. Elevated ΔCD47, ΔPD-L1 (SP142) were IRFs for poor prognosis in NSCLC patients. The area under the curve of ΔCD47, ΔPD-L1 (SP142) and their combination for predicting NSCLC poor prognosis were separately 0.801, 0.797 and 0.891. Elevated ΔCD47 and ΔPD-L1 (SP142) shortened OS, PFS, and increased mortality risk in patients.
conclusionsPost-NAT CD47 and PD-L1 (SP142) levels were reduced in IIIA-N2 NSCLC patients. ΔCD47 and ΔPD-L1 (SP142) levels linked to clinicopathological characteristics and predicted prognosis.
Indexed as
Identifiers
41307632What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.